Compare DGICB & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICB | DNA |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.0M | 562.3M |
| IPO Year | N/A | N/A |
| Metric | DGICB | DNA |
|---|---|---|
| Price | $17.55 | $8.71 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 3.5K | ★ 1.0M |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | ★ 219.91 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $987,826,105.00 | $180,606,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | $3.46 | $7.28 |
| P/E Ratio | $8.14 | ★ N/A |
| Revenue Growth | ★ 0.89 | N/A |
| 52 Week Low | $13.19 | $5.00 |
| 52 Week High | $20.46 | $17.58 |
| Indicator | DGICB | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 47.52 |
| Support Level | $15.96 | $8.08 |
| Resistance Level | $17.71 | $9.12 |
| Average True Range (ATR) | 0.35 | 0.52 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 92.12 | 31.50 |
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.